BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, January 8, 2026
Breaking News: BioWorld Science 2025 Year in Review
See today's BioWorld Science
Home
» CLDN6-23-ADC shows promise for ovarian, endometrial tumors
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
CLDN6-23-ADC shows promise for ovarian, endometrial tumors
Feb. 29, 2024
Claudin-6 (CLDN6) is highly expressed in several cancer types, including ovarian and endometrial cancers, while very low or no expression is found in normal tissues.
BioWorld Science
Conferences
Cancer
Women's health
Antibody-drug conjugate
Immuno-oncology